← Back to Search

Behavioral Intervention

Non-Medication Pain Management Strategies for Chronic Pain (OPTIONS Trial)

N/A
Recruiting
Led By Marianne Sassi Matthias, PhD MS BA
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 6 months
Awards & highlights

Summary

This trial teaches Veterans how to manage chronic pain without medications, with a coach to help explore their values and goals.

Who is the study for?
This trial is for Veterans with chronic musculoskeletal pain in the low back, neck, or limbs lasting at least 3 months. Participants should be open to non-medication treatments and have moderate pain affecting their life. They must not have severe cognitive issues, active suicidal thoughts, long-term opioid use, recent psychiatric hospitalization, or serious medical conditions like advanced heart failure.
What is being tested?
The study explores nonpharmacological strategies for managing chronic pain among Veterans. It involves working with a coach to align various non-medication approaches with the participants' values and goals in relation to their chronic pain management.
What are the potential side effects?
Since this trial focuses on nonpharmacological methods of managing pain (like physical therapy or mindfulness), it does not involve medication; therefore, typical drug side effects are not expected. However, some discomfort may arise from trying new activities.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain
Secondary study objectives
Anxiety
Decisional Conflict Scale
Depression PHQ-8
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: OPTIONS Intervention CoachingExperimental Treatment1 Intervention
Intervention participants will participate in a series of four coaching sessions focused on helping patients clarify their values and treatment goals, aligning these values and goals and their lifestyle with nonpharmacological treatment options, working on overcoming barriers to use and adherence of nonpharmacological treatment options (using motivational interviewing), and preparing patients to discuss these options with their primary care providers. A decision aid will be used during these coaching sessions.
Group II: OPTIONS Waitlist ControlActive Control1 Intervention
Participants randomized into waitlist control group will receive the intervention decision aid after completing the last survey at 9 months. Participants will also be offered the opportunity to have a brief 20-minute session with a member of the OPTIONS study staff to help walk them through this decision aid.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,647 Previous Clinical Trials
3,359,774 Total Patients Enrolled
21 Trials studying Pain
4,948 Patients Enrolled for Pain
Marianne Sassi Matthias, PhD MS BAPrincipal InvestigatorRichard L. Roudebush VA Medical Center, Indianapolis, IN
3 Previous Clinical Trials
485 Total Patients Enrolled
2 Trials studying Pain
465 Patients Enrolled for Pain

Media Library

Options for Pain Management using Non-medication Strategies (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05563792 — N/A
Pain Research Study Groups: OPTIONS Intervention Coaching, OPTIONS Waitlist Control
Pain Clinical Trial 2023: Options for Pain Management using Non-medication Strategies Highlights & Side Effects. Trial Name: NCT05563792 — N/A
Options for Pain Management using Non-medication Strategies (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05563792 — N/A
~120 spots leftby Dec 2025